Stephanie Tagliatela, CSO, will present Restoring SCN1A Mediated Neuronal Excitability Through Cell Selective Gene Regulation in Clinical Dravet Syndrome at the Ion Channel Targeted Drug Discovery Summit in Boston: bit.ly/3UVOpHu #ionchannels

We’re hiring across #SupplyChain, #InternalManufacturing, and #QualityAssurance to support our expanding development and manufacturing operations in NC. Learn more: Careers – Encoded Therapeutics ow.ly/McEZ50ZPSws #GeneTherapy #BiotechCareers #BiotechJobs

#EEC2026: Prof. Ingrid Scheffer, University of Melbourne, presented new POLARIS data, Emma James, Encoded, contributed to a mini-forum on disease-modification trials, and the team met with leaders across the epilepsy community. Here’s the data release: encoded.com/encoded-therapeu…

We closed a $275 million financing co-led by GV and another healthcare fund, with support from new and existing investors. Funding will advance ETX101 for Dravet syndrome and support broader pipeline advancement. Learn more encoded.com/encoded-therapeu…

Professor Ingrid Scheffer of the University of Melbourne will present new ETX101 data during a platform presentation at #EEC2026 on September 7. Learn more: ow.ly/oGxF50ZIn6G

At the 2026 BRAIN Initiative Conference, Stephanie Tagliatela, CSO, joins the Aug 13 session on Precision Molecular Circuit Therapies. Encoded is proud to contribute. #BRAINconference

Proud to sponsor the Epilepsy Pipeline Conference. Catch JosephSullivan presenting interim Phase 1/2 data for ETX101 in #DravetSyndrome on 6/19. #EpilepsyPipeline2026

June is #DravetAwarenessMonth — an opportunity to raise awareness and recognize the experiences of individuals and families affected by Dravet syndrome. Dravet syndrome is often described as a “severe epilepsy,” but its effects can extend beyond seizures, impacting development, behavior, sleep, mobility, and temperature regulation. This month, we stand with the Dravet community and reaffirm our commitment to advancing science that brings real hope closer to reality. Learn more at the Dravet Syndrome Foundation website: bit.ly/4dObPnJ #curedravet #advocatefordravet @curedravet

Great article from Endpoints News today highlighting our latest ETX101 data in #DravetSyndrome presented at #ASGCT2026. Check out the article here: endpoints.news/encodeds-gene… endpoints.news/encodeds-gene…

Appreciating the coverage from @BiotechTV on our latest ETX101 data in #DravetSyndrome presented at #ASGCT2026. Thanks for helping share the story.

Big moment at #ASGCT2026 today! Read our release for details on ETX101 data in #dravetsyndrome being featured today in the Presidential Symposium presentation: bit.ly/4djirul

Today’s release shares preclinical data from #ASGCT2026 showing the potential of our precision vector engineering platform to enable one time gene therapies. bit.ly/4ntVZU4

Announcing strong pipeline momentum with new milestones for ETX101 in Dravet syndrome and ETX301, our candidate for post-amputation neuroma pain. Learn more: bit.ly/4wbByPn

Don’t miss Dr. Joe Sullivan, VP Clinical Development, speaking in Session 12 at #EILATXVIII on Developing Gene Therapies for DEEs on May 6.

Encoded will present data and insights from our POLARIS program for ETX101 for Dravet syndrome at #EILATXVIII on 5/ 4 from 4:15 – 4:35 CET. Learn more: bit.ly/3P4z7NY

We’re back from Epilepsy Awareness Day presented by Sofie's Journey. We’re grateful for the opportunity to connect with the epilepsy community in a meaningful way and for the insights that directly shape how we show up as partners. Thank you to everyone – patients, physicians, and other collaborators – who spent time and shared their stories with us. We’re inspired to carry this momentum forward — grounded in real experiences and focused on what matters most.

Encoded is headed to #ASGCT2026, where we’ll present three abstracts — an oral presentation in the Presidential Symposium highlighting continued progress with ETX101, and two scientific posters showcasing our vector engineering approach and its potential to deliver precision one time genetic medicines for neurological disorders. Details are below and in the link: ow.ly/azgZ50YQNTj Oral Presentation: Safety and Efficacy of ETX101, an Investigational AAV9-based Gene Therapy for SCN1A+ Dravet Syndrome: Interim Results from the POLARIS Phase 1/2 Clinical Trials • Session: General Session: Presidential Symposium • Location: Exhibit Hall B1 (Exhibit Level) • Date and Time: Wednesday, May 13, 2026; 2:26 PM – 2:37 PM ET Poster Presentation: NociPro: A Novel Modality-Agnostic Promoter Platform for Precise Cellular Targeting of Nociceptor Sensory Neurons in Gene Therapy for Chronic Pain • Abstract Number: 1312 • Location: Poster Hall • Date and Time: Tuesday, May 12, 2026; 5:00 PM – 6:30 PM ET Poster Presentation: An Experimental Intravenous AAV-miRNA-based Approach Achieves Broad Neuronal Transduction and UBE3A Unsilencing for the Treatment of Angelman Syndrome • Abstract Number: 1468 • Location: Poster Hall • Date and Time: Tuesday, May 12, 2026; 5:00 PM – 6:30 PM ET

Thank you, @neurology_live, for featuring our POLARIS program for ETX101 for Dravet syndrome in this month’s Clinical Trial in Focus. Every opportunity to elevate the science—and the needs of this community—helps move us closer to meaningful, lasting change for patients and caregivers. neurologylive.com/view/explo…